

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

InVivoMAb anti-mouse CD20

RRID:AB_2894775

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0356, RRID:AB_2894775)

Antibody Information

URL: http://antibodyregistry.org/AB_2894775

Proper Citation: (Bio X Cell Cat# BE0356, RRID:AB_2894775)

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo Cell Specific Depletion, Western Blot

Antibody Name: InVivoMAb anti-mouse CD20

Description: This monoclonal targets CD20

Target Organism: mouse

Clone ID: clone MB20-11

Antibody ID: AB_2894775

Vendor: Bio X Cell

Catalog Number: BE0356

Alternative Catalog Numbers: BE0356-50MG, BE0356-25MG, BE0356-1MG, BE0356-100MG, BE0356-5MG

Record Creation Time: 20260114T193253+0000

Record Last Update: 20260623T051053+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMAb anti-mouse CD20.

No alerts have been found for InVivoMAb anti-mouse CD20.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. *Cancer cell*.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Cao S, et al. (2024) Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy. *Cell reports. Medicine*, 5(1), 101346.

Yakkala C, et al. (2024) Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4190.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. *Cell reports. Medicine*, 5(3), 101448.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. *Cancer cell*, 42(1), 85.

Jin Y, et al. (2023) Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication. *Cell reports. Medicine*, 4(6), 101043.

Wattenberg MM, et al. (2023) Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. *Science immunology*, 8(89), eadj5097.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.